Vididencel is under clinical development by Mendus and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase II drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vididencel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
vididencel is under development for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome, high-grade serous ovarian cancer and multiple myeloma. It is administered intradermally and formulated solution and is a dendritic cell vaccine. The drug is developed based on proprietary DCOne platform. The DCOne cell line is derived from a patient with acute myeloid leukemia (AML) and expresses multiple AML-specific antigens.
Mendus, formerly Immunicum, develops allogeneic and off-the-shelf cell-based therapies for treating solid tumors. The company’s product candidate ilixadencel, an intratumoral immune primer is used for the treatment of renal cell cancer, gastrointestinal stromal tumors, multiple solid tumors and kidney, liver and hepatocellular cancer. Mendus another product DCP-001 is a cancer relapse vaccine that is derived from the DCOne leukemic cell line to treat acute myeloid leukemia and ovarian cancer. The company works in partnership with academic research groups, pharmaceutical and biotech companies to develop and commercialize new therapeutics. It operates a research and development facility in Leiden, The Netherlands. Mendus is headquartered in Stockholm, Sweden.
For a complete picture of Vididencel’s drug-specific PTSR and LoA scores, buy the report here.